Protagonist Therapeutics, Inc. (PTGX) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin -282.8%, revenue growth 99.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $46.02M |
| Revenue (TTM) | $0.1B |
| Net Margin | -282.8% |
| Operating Margin (TTM) | -192.4% |
| Revenue Growth (YoY) | 99.0% |
| EPS Growth (YoY) | -131.6% |
| FCF Growth (YoY) | -139.4% |
| Price / Book | 15.14 |
| Price / Sales | 134.01 |
| FCF Yield | -1.2% |
| Altman Z-Score | 109.74 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
PTGX overview · PTGX earnings · PTGX KPIs · PTGX documents · PTGX ownership · PTGX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.